Pages that link to "Q37457321"
Jump to navigation
Jump to search
The following pages link to Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference (Q37457321):
Displaying 50 items.
- Effects of systemic immunosuppressive therapies for moderate-to-severe eczema in children and adults (Q24188221) (← links)
- Systemic Treatment of Pediatric Psoriasis: A Review (Q26753026) (← links)
- Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis? (Q26767276) (← links)
- Hepatic manifestations of non-steroidal inflammatory bowel disease therapy (Q26773684) (← links)
- Management of inflammatory bowel disease in pregnancy (Q26865914) (← links)
- Management of psoriasis patients with hepatitis B or hepatitis C virus infection (Q28078157) (← links)
- Inflammatory bowel diseases and human reproduction: a comprehensive evidence-based review (Q28388274) (← links)
- Psoriasis and comorbid diseases: Implications for management (Q30235888) (← links)
- Cell-penetrating peptides released from thermosensitive nanoparticles suppress pro-inflammatory cytokine response by specifically targeting inflamed cartilage explants (Q33552879) (← links)
- Methotrexate-induced cutaneous ulceration in 3 nonpsoriatic patients: Report of a rare side effect (Q33571728) (← links)
- Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease (Q33654733) (← links)
- Methotrexate in a Real-World Psoriasis Treatment: Is It Really a Dangerous Medication for All? (Q33710680) (← links)
- Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity (Q33841403) (← links)
- Incidence of liver toxicity in inflammatory bowel disease patients treated with methotrexate: a meta-analysis of clinical trials (Q33959573) (← links)
- Methotrexate: underused and ignored? (Q34321255) (← links)
- Systemic methotrexate therapy for psoriasis: past, present and future. (Q34356265) (← links)
- Psoriasis and comorbidities: links and risks (Q34418506) (← links)
- A phase I trial to evaluate the safety and pharmacokinetics of low-dose methotrexate as an anti-malarial drug in Kenyan adult healthy volunteers (Q34770054) (← links)
- Psoriasis and the risk of pneumonia: a population-based study (Q34777002) (← links)
- The possibilities and principles of methotrexate treatment of psoriasis - the updated knowledge (Q34945967) (← links)
- The cost of biologics for psoriasis is increasing (Q34973745) (← links)
- Significance of liver biopsy for the evaluation of methotrexate-induced liver damage in patients with rheumatoid arthritis (Q35405041) (← links)
- Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents (Q35539576) (← links)
- An unusual case of acute methotrexate toxicity manifesting as ulcers on psoriatic plaques in an elderly male (Q35929533) (← links)
- Oral clindamycin causing acute cholestatic hepatitis without ductopenia: a brief review of idiosyncratic drug-induced liver injury and a case report (Q36182393) (← links)
- Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases (Q36372720) (← links)
- A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. (Q36417100) (← links)
- Prevalence and risk factors of methotrexate hepatoxicity in Asian patients with psoriasis (Q36876383) (← links)
- Metabolic syndrome in patients with psoriatic disease. (Q36897095) (← links)
- Safety and efficacy of immunomodulators and biologics during pregnancy and lactation for the treatment of inflammatory bowel disease (Q36989959) (← links)
- The antifolates (Q37183495) (← links)
- Low-dose methotrexate results in the selective accumulation of aminoimidazole carboxamide ribotide in an erythroblastoid cell line (Q37193206) (← links)
- An evolution in switching therapy for psoriasis patients who fail to meet treatment goals (Q37295966) (← links)
- Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations (Q37492482) (← links)
- Alefacept: where it stands today (Q37693964) (← links)
- Low dosages: new chemotherapeutic weapons on the battlefield of immune-related disease (Q37728232) (← links)
- Psoriatic arthritis: pharmacotherapy update (Q37758453) (← links)
- Topical delivery for the treatment of psoriasis (Q37774344) (← links)
- Psoriasis and non-alcoholic fatty liver disease. (Q37788777) (← links)
- Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic (Q37825556) (← links)
- Advances in the treatment of moderate-to-severe plaque psoriasis (Q37868389) (← links)
- Management of psoriatic arthritis from the view of the dermatologist (Q37930978) (← links)
- The use of methotrexate in dermatology: a review (Q37981730) (← links)
- The effects of alcohol on the metabolism and toxicology of anti-psoriasis drugs (Q38010769) (← links)
- Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents (Q38098466) (← links)
- Diagnosis and treatment of pediatric psoriasis: current and future (Q38107168) (← links)
- Diagnosing and treating psoriatic arthritis: an update (Q38165235) (← links)
- Hepatotoxicity caused by methotrexate therapy in children with inflammatory bowel disease: a systematic review and meta-analysis (Q38166551) (← links)
- Folate supplementation reduces the side effects of methotrexate therapy for psoriasis. (Q38223934) (← links)
- A review of methotrexate-associated hepatotoxicity (Q38241492) (← links)